Glucose dependency of arginine vasopressin-induced insulin and glucagon release from the perfused rat pancreas
- PMID: 12200765
- DOI: 10.1053/meta.2002.34052
Glucose dependency of arginine vasopressin-induced insulin and glucagon release from the perfused rat pancreas
Abstract
The purpose of this study was to investigate the glucose dependency of arginine vasopressin (AVP)-induced insulin, glucagon, and somatostatin release from the perfused rat pancreas. AVP (30 or 300 pmol/L) was tested in the presence of a glucose concentration of 0, 1.4, 5.5 (basal level), or 20 mmol/L. The rates of insulin release at 0 and 1.4 mmol/L glucose were approximately 70% to 80% and 60% to 70% less, respectively, than that at the baseline level. AVP (30 or 300 pmol/L) failed to change insulin release at 0 and 1.4 mmol/L glucose. At the basal glucose level, AVP (300 pmol/L) induced a biphasic insulin release, a peak followed by a sustained phase. In addition, the combination of glucose (20 mmol/L) and AVP (300 pmol/L) induced a higher insulin peak and sustained phase than 20 mmol/L glucose alone. The rates of glucagon release at 0 and 1.4 mmol/L glucose were about 3- and 2-fold more, respectively, than that at the baseline level. At 0 and 1.4 mmol/L glucose, both 30 and 300 pmol/L AVP caused a higher glucagon peak and sustained phase than 0 and 1.4 mmol/L glucose alone. At the basal glucose level, AVP (30 or 300 pmol/L) induced a biphasic glucagon release, a peak followed by a sustained phase. The rate of glucagon release at 20 mmol/L glucose was approximately 60% to 70% less than that at the baseline level. When AVP (300 pmol/L) was administered in 20 mmol/L glucose, it induced a transient glucagon peak, which was 2.4-fold of the baseline level. At all glucose concentrations tested, AVP (30 or 300 pmol/L) failed to change somatostatin release. These results suggested that (1) hypoglycemia directly increases glucagon and decreases insulin release; (2) AVP induces insulin and glucagon release by a direct action on beta and alpha cells, respectively; (3) AVP induces insulin and glucagon release in a glucose-dependent manner-the higher the glucose concentration, the greater the enhancement of AVP-induced insulin release, whereas the lower the glucose concentration, the higher the enhancement of AVP-induced glucagon release; and (4) alpha cells are more sensitive to AVP than beta cells in hormone release.
Copyright 2002, Elsevier Science (USA). All rights reserved.
Similar articles
-
Glucagon is paradoxically secreted at high concentrations of glucose in rat pancreas perfused with diazoxide.Diabetes Nutr Metab. 2002 Aug;15(4):260-4. Diabetes Nutr Metab. 2002. PMID: 12416665
-
Modulation of insulin and glucagon secretion from the perfused rat pancreas by the neurohypophysial hormones and by desamino-D-arginine vasopressin (DDAVP).Peptides. 1984 Sep-Oct;5(5):871-5. doi: 10.1016/0196-9781(84)90109-8. Peptides. 1984. PMID: 6390359
-
Difference in calcium dependency of insulin, glucagon and somatostatin secretion in response to glibenclamide in perfused rat pancreas.Diabetologia. 1982 Jun;22(6):475-9. doi: 10.1007/BF00282593. Diabetologia. 1982. PMID: 6125449
-
The interaction of vasoactive intestinal polypeptide (VIP), glucose and arginine on the secretion of insulin, glucagon and somatostatin in the perfused rat pancreas.Diabetologia. 1980 Aug;19(2):137-42. doi: 10.1007/BF00421860. Diabetologia. 1980. PMID: 6106616
-
Molecular Interaction Between Vasopressin and Insulin in Regulation of Metabolism: Impact on Cardiovascular and Metabolic Diseases.Int J Mol Sci. 2024 Dec 11;25(24):13307. doi: 10.3390/ijms252413307. Int J Mol Sci. 2024. PMID: 39769071 Free PMC article. Review.
Cited by
-
Copeptin adaptive response to SGLT2 inhibitors in patients with type 2 diabetes mellitus: The GliRACo study.Front Neurosci. 2023 Mar 20;17:1098404. doi: 10.3389/fnins.2023.1098404. eCollection 2023. Front Neurosci. 2023. PMID: 37021137 Free PMC article.
-
Plasma copeptin and the risk of diabetes mellitus.Circulation. 2010 May 18;121(19):2102-8. doi: 10.1161/CIRCULATIONAHA.109.909663. Epub 2010 May 3. Circulation. 2010. PMID: 20439785 Free PMC article.
-
Increased copeptin may reflect vasopressin-related metabolic changes after bariatric surgery.Obesity (Silver Spring). 2025 Feb;33(2):298-307. doi: 10.1002/oby.24200. Epub 2024 Dec 26. Obesity (Silver Spring). 2025. PMID: 39725569 Free PMC article.
-
Long-term health outcomes associated with hydration status.Nat Rev Nephrol. 2024 May;20(5):275-294. doi: 10.1038/s41581-024-00817-1. Epub 2024 Feb 26. Nat Rev Nephrol. 2024. PMID: 38409366 Review.
-
Arginine vasopressin: Direct and indirect action on metabolism.Peptides. 2021 Aug;142:170555. doi: 10.1016/j.peptides.2021.170555. Epub 2021 Apr 24. Peptides. 2021. PMID: 33905792 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous